Laden... Bitte warten
Company profile
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Source:
Cofisem
-
Last Update:
26 Mar 2025
Key Executives
| Chief Executive Officer | Tim Van Hauwermeiren | ||||
| Chief Financial Officer | Karl Gubitz | ||||
| Chief Communication Officer | Beth DelGiacco | ||||
| Head of Investor Relations | Beth DelGiacco | ||||
| Chief Strategy and Development Officer | Arjen Lemmen | ||||
| Chief Operating Officer | Karen Massey | ||||
| Chief Human Resources Officer | Marc Schorpion | ||||
| Source: Cofisem - Last Update: 26 Mar 2025 | |||||
Key figures
| Millenium | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Net sales | 2.190.231 | 1.226.316 | 410.746 | 497.277 | 41.243 |
| Income from ordinary activities | 2.252.039 | 1.268.594 | 410.746 | 497.277 | 41.243 |
| Operating income | -21.654 | -425.049 | -720.341 | -348.746 | -477.617 |
| Cost of financial indebtedness net | -138.740 | -92.962 | -24.741 | -3.489 | -5.119 |
| Equity-accounted companies contribution to income | |||||
| Net profit from discontinued activities | |||||
| Net income | 833.040 | -295.053 | -709.594 | -408.265 | -608.455 |
| Net income (Group share) | 833.040 | -295.053 | -709.594 | -408.265 | -608.455 |
| Fiscal year end | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | USD - thousands | USD - thousands | USD - thousands | USD - thousands | USD - thousands |
| Account Standards | IFRS | IFRS | IFRS | IFRS | IFRS |
| Source: Cofisem - Last Update: 26 Mar 2025 | |||||
Shareholder information
Adresse
argenx SE
Laarderhoogtweg 25
NL-1101 EB
Amsterdam
Netherlands
Telefonnummer:
+31 (0) 763 030 488
Source:
Cofisem
-
Last Update:
26 Mar 2025